These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 28975580)

  • 21. Vitamin D, vitamin D binding protein, vitamin D receptor levels and cardiac dysautonomia in patients with multiple sclerosis: a cross-sectional study.
    Aktürk T; Turan Y; Tanik N; Karadağ ME; Sacmaci H; Inan LE
    Arq Neuropsiquiatr; 2019 Dec; 77(12):848-854. PubMed ID: 31939581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis.
    Gava G; Bartolomei I; Costantino A; Berra M; Venturoli S; Salvi F; Meriggiola MC
    Fertil Steril; 2014 Jul; 102(1):116-22. PubMed ID: 24794311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship of CSF neurotransmitter metabolite levels to disease severity and disability in multiple sclerosis.
    Markianos M; Koutsis G; Evangelopoulos ME; Mandellos D; Karahalios G; Sfagos C
    J Neurochem; 2009 Jan; 108(1):158-64. PubMed ID: 19014375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-fat, plant-based diet in multiple sclerosis: A randomized controlled trial.
    Yadav V; Marracci G; Kim E; Spain R; Cameron M; Overs S; Riddehough A; Li DK; McDougall J; Lovera J; Murchison C; Bourdette D
    Mult Scler Relat Disord; 2016 Sep; 9():80-90. PubMed ID: 27645350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis.
    Stein MS; Liu Y; Gray OM; Baker JE; Kolbe SC; Ditchfield MR; Egan GF; Mitchell PJ; Harrison LC; Butzkueven H; Kilpatrick TJ
    Neurology; 2011 Oct; 77(17):1611-8. PubMed ID: 22025459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Severe disability in patients with relapsing-remitting multiple sclerosis is associated with profound changes in the regulation of leptin secretion.
    Rotondi M; Batocchi AP; Coperchini F; Caggiula M; Zerbini F; Sideri R; Leporati P; Nociti V; Frisullo G; Mirabella M; Magri F; Oliviero A; Chiovato L
    Neuroimmunomodulation; 2013; 20(6):341-7. PubMed ID: 24008588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
    Shirani A; Zhao Y; Karim ME; Evans C; Kingwell E; van der Kop ML; Oger J; Gustafson P; Petkau J; Tremlett H
    JAMA; 2012 Jul; 308(3):247-56. PubMed ID: 22797642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Longitudinal disability curves for predicting the course of relapsing-remitting multiple sclerosis.
    Achiron A; Barak Y; Rotstein Z
    Mult Scler; 2003 Oct; 9(5):486-91. PubMed ID: 14582775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intrathecal IgM index correlates with a severe disease course in multiple sclerosis: Clinical and MRI results.
    Ozakbas S; Cinar BP; Özcelik P; Baser H; Kosehasanoğullari G
    Clin Neurol Neurosurg; 2017 Sep; 160():27-29. PubMed ID: 28622533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis.
    Soilu-Hänninen M; Laaksonen M; Laitinen I; Erälinna JP; Lilius EM; Mononen I
    J Neurol Neurosurg Psychiatry; 2008 Feb; 79(2):152-7. PubMed ID: 17578859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retinal nerve fiber layer thickness and neurologic disability in relapsing-remitting multiple sclerosis.
    Behbehani R; Al-Hassan AA; Al-Khars A; Sriraman D; Alroughani R
    J Neurol Sci; 2015 Dec; 359(1-2):305-8. PubMed ID: 26671132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Magnetization transfer magnetic resonance imaging and clinical changes in patients with relapsing-remitting multiple sclerosis.
    Oreja-Guevara C; Charil A; Caputo D; Cavarretta R; Sormani MP; Filippi M
    Arch Neurol; 2006 May; 63(5):736-40. PubMed ID: 16682543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b.
    Fitzgerald KC; Munger KL; Köchert K; Arnason BG; Comi G; Cook S; Goodin DS; Filippi M; Hartung HP; Jeffery DR; O'Connor P; Suarez G; Sandbrink R; Kappos L; Pohl C; Ascherio A
    JAMA Neurol; 2015 Dec; 72(12):1458-65. PubMed ID: 26458124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
    Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
    Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Down-regulation of CYP27B1 gene expression in Iranian patients with relapsing-remitting multiple sclerosis.
    Rezaie Z; Taheri M; Kohan L; Sayad A
    Hum Antibodies; 2016; 24(3-4):71-76. PubMed ID: 27792005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating vitamin D binding protein levels are not associated with relapses or with vitamin D status in multiple sclerosis.
    Smolders J; Peelen E; Thewissen M; Menheere P; Damoiseaux J; Hupperts R
    Mult Scler; 2014 Apr; 20(4):433-7. PubMed ID: 23959712
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multimodal evoked potentials measure and predict disability progression in early relapsing-remitting multiple sclerosis.
    Jung P; Beyerle A; Ziemann U
    Mult Scler; 2008 May; 14(4):553-6. PubMed ID: 18562509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
    Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple Sclerosis Impact Scale (MSIS-29): relation to established measures of impairment and disability.
    Hoogervorst EL; Zwemmer JN; Jelles B; Polman CH; Uitdehaag BM
    Mult Scler; 2004 Oct; 10(5):569-74. PubMed ID: 15471375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.